Acute Kidney Injury Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Acute Kidney Injury remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 1,006 matched trial records and 160 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07683975 | Infliximab + Prednisone | Phase 4; Not yet recruiting | The Massachusetts General Hospital | United States | Acute kidney injury recovery at 12 weeks (12 weeks) | 2029-01-15 |
| NCT07685587 | Intervention not normalized | Not Applicable; Recruiting | Sponsor not listed | Turkey | acute kidney injury (preoperative, postoperative 24th hour and postoperative 7. days) | 2027-06-30 |
| NCT07681817 | Intervention not normalized | Not Applicable; Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | Geography not listed | Postoperative acute kidney injury incidence (AKI was assessed within the first 7 days following interventional therapy) | 2027-12-31 |
| NCT07679568 | Intervention not normalized | Not Applicable; Not yet recruiting | Fresenius Medical Care Deutschland GmbH | Germany | Rate of clearance (Creatinine reduction in blood and effluent) as therapy efficacy at specified time points (From enrollment up to 10 days); Assessment of potential electrolyte imbalances or acid base disturbances during RCA treatment (From enrollment up to 10 days) | 2027-06-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Inhaled nitric oxide for reducing major adverse events requiring intensive life support in adults undergoing cardiac surgery with cardiopulmonary bypass: protocol for a phase III, double-blind, multicenter randomized controlled trial (NORISC Trial) (Phase 3): the indexed record reports -; Composite endpoint(30-day all-cause mortality and major adverse events (MAEs) necessitating intensive life support) = 16.0 %.
- Association of duration of amino acids infusion and renal protection: a secondary analysis of the PROTECTION trial (Phase 3): the indexed record reports AKI = Brief and prolonged AA infusion had similar magnitude and direction of effect on AKI (interaction P=0.89), with a risk reduction of 3.8% (25% to 21%) and 5.7% (44% to 38%), respectively.; AKI = Brief and prolonged AA infusion had similar magnitude and direction of effect on AKI (interaction P=0.89), with a risk reduction of 3.8% (25% to 21%) and 5.7% (44% to 38%), respectively..
- A Randomized, Multi-centric, Placebo-controlled, Participant and Investigator-blinded Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Adult Patients at Risk for Acute Kidney Injury Following Cardiac Surgery. (Phase 2): the indexed record reports Ratio of the Highest Serum Creatinine Value up to and Including Study Day 6 Versus Baseline(Geometric Mean) = 1.226 ratio (90% Confidence Interval, 1.08 - 1.39); Ratio of the Highest Serum Creatinine Value up to and Including Study Day 6 Versus Baseline(Geometric Mean): geometric mean ratio = 0.991(90% CI, 0.87 - 1.13), P-Value = 0.4543; geometric mean ratio = 1.075(90% CI, 0.97 - 1.20), P-Value = 0.8667; Ratio of the Highest Serum Creatinine Value up to and Including Study Day 6 Versus Baseline(Geometric Mean) = 1.318 ratio (90% Confidence Interval, 1.18 - 1.48).
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Infliximab (Approved; TNF-α), Prednisone (Approved; GR). Company & Deal Intelligence records identify sponsor context for The Massachusetts General Hospital, Tianjin Medical University Cancer Institute and Hospital, Fresenius Medical Care Deutschland GmbH (FME). Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Acute Kidney Injury has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
